Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Behrang Amini

Showing results (171-180 of 173) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 173 results.
Journal of Neurosurgery. Spine|June 20, 2025
Sacral fracture risk after stereotactic spinal radiosurgery: a multi-institution, retrospective analysisEric A Goethe, Romulo A Andrade de Almeida, Francisco Call-Orellana, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2020
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancerKyle G Mitchell, Behrang Amini, Yunfei Wang, et al.
The Lancet. Oncology|August 7, 2022
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trialNeeta Somaiah, Anthony P Conley, Edwin Roger Parra, et al.
Pageof 18

Showing results (171-180 of 173) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 173 results.
Journal of Neurosurgery. Spine|June 20, 2025
Sacral fracture risk after stereotactic spinal radiosurgery: a multi-institution, retrospective analysisEric A Goethe, Romulo A Andrade de Almeida, Francisco Call-Orellana, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2020
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancerKyle G Mitchell, Behrang Amini, Yunfei Wang, et al.
The Lancet. Oncology|August 7, 2022
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trialNeeta Somaiah, Anthony P Conley, Edwin Roger Parra, et al.
Pageof 18